Bionetwork west 2010

Don’t Get Lost In The “Cattle Call” Of The Too-Big Industry Events. SpendQuality Time With The Right People At BioNetwork.

Source Funding. Forge Partnerships. Manage Relationships.

October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CAwww.bionetworkus.com

Sponsors: Organized by:

• Gain insights from an unmatched speaker faculty and delegate base all eager to network and share knowledge• Maximize over 14 hours of networking activities built into the agenda so that you can have meaningful

conversations over the course of three days• 1:1 partnering software makes it easy for you to schedule private meetings with our speakers and delegates

before you get to the conference• Onsite facebook allows you to put a face to a name while at the conference. That way you can easily pinpoint

who you want to speak with, instead of sifting through a sea of nametags

PLUS - 2 Full Afternoons Of The Perfect Pitch – Biotech Investment Challenge! In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts who will provide them with invaluable feedback to strengthen their pitches.

Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535Email: [email protected] Web: www.bionetworkus.com

REGISTERNOW!

Martin ReevesVice President, BusinessDevelopmentCephalon

Gregg TalbertManaging Director, Mergers andAcquisitions, Corporate Finance andInvestment Banking (CFIB) GroupEli Lilly

Robert WillsVice President Alliance Management,Pharmaceuticals GroupJohnson & Johnson

Ellen A. LubmanStrategic Transactions GroupBristol-Myers Squibb

James SchaefferExecutive Director, WorldwideLicensing and External ResearchMerck

Chris SeatonSenior Vice President, GlobalTransactionsBayer HealthcarePharmaceuticals

Robert BagdorfVice President, WorldwideBusiness DevelopmentPfizer Inc.

David DonabedianVice President, StrategicAlliances, US CEEDDGlaxoSmithKline

Kimberly RogersVice President, TechnologyAssessmentAllergan

Special DiscountsAvailable!See pg. 7 for details

Top Speakers You Will Meet At BioNetwork:

New And Improved Networking OpportunitiesWe make sure that you meet the people you came to see.

Onsite FacebookTired of sifting through a sea of name tags to find the person you want to meet? Upon check-in, theBioNetwork team will be taking photos of all speakers and attendees so that you can easily spot the personyou wish to network with.

Onsite Message BoardPlaced in a central location by the registration area, the onsite message board allows you to leave notes forspeakers or attendees that you are looking to connect with while at BioNetwork West.

Schedule Meetings Before You Arrive!These pre-arranged rooms are available to be booked for 30 minute time blocks. 6 weeks out fromBioNetwork West 2010, you will receive a password allowing you to schedule One-To-One PrivatePartnering Rooms online. On our website you will find a list of registered attendees along with their contactdetails (viewable at their discretion), a brief description of their companies and partnership aspirations and atimetable of available meeting rooms. Upon receiving an accepted invitation from a potential partner, youwill be able to schedule a private partnering room. Please contact Sarah Cascone with any questionsregarding the one-to-one partnering site at [email protected] or 646-200-7497.

Improved One-To-One PrivatePartnering Technology!

• Internal messaging capability• Scheduling blocking function• Personalized meeting requests designed to avoid

spam filters • Conference agenda accessible through partnering

software

You have the opportunity to reserve the One-To-OnePrivate Partnering Rooms for all three days ofBioNetwork West where you can privately discuss thespecifics of your companies, your goals, and yourcompounds.

*To view Who You Are Going To Meet AtBioNetwork, please visit the websitewww.bionetworkus.com.

7:45 Networking Breakfast For All Attendees Conference Registration Sponsored By:

8:30 Chairperson’s Opening Remarks

8:45 Panel Session: Assessing The Deal-Making Landscape For 2010 -A Reflective Look At The Deals Done This Past Year

Martin ReevesVice President Business DevelopmentCephalon

Jim HattersleyVice President Corporate Business DevelopmentSun Pharmaceutical Industries, Inc.

Paul DarlingPrincipalZS Associates

John HebertAssociate Director, Corporate DevelopmentGenzyme

Much has happened in the pharmaceutical space in the past year. Now is theperfect time to get a read on how the industry fared in 2010. This openingpanel session will analyze important developments in 2010 and its impact onthe industry on a larger scale: Outlining major deals in 2010; evaluatingfinancing in 2010; updates on the IPO window; Increase in foreign companiesbuying into the US market and who’s partnering with whom?

9:30 Panel Session: Industry Outlook - What Will The Pharma SpaceLook Like In 5 Years?

Chris SeatonSenior Vice President, Global TransactionsBayer HealthCare Pharmaceuticals

Robert BagdorfVice President, Worldwide Business DevelopmentPfizer Inc.

Executive Speaker and Panel ModeratorCampbell Alliance

In the wake of healthcare reform, the economic recession, industryconsolidation and the patent cliff the pharmaceutical space has seenconsiderable changes that will only continue. This session will look at thepharmaceutical industry outlook and provide predictions for what we canexpect in the coming years: impact of the healthcare reform on R&D and BD;effects of industry consolidation; how will big Pharma offset the negativeimpact of dwindling pipelines.

10:15 Refreshment Break And Networking Opportunity

11:00 Case Study: BMS And Allergan Global Agreement ForInvestigational Neuropathic Pain Medicine

Tim HerpinDirector, Search and Evaluation, Strategy, Alliances and TransactionsBristol-Myers Squibb

Kimberly RogersVice President Technology AssessmentAllergan

This case study will look at the recent deal between BMS and Allergan forAllergan’s experimental therapy for neuropathic pain. This session will look intothe strategic considerations behind the partnership from both BMS andAllergan's perspectives and delve into the steps and timelines of the partneringprocess, the due diligence experience, and the status of the relationship today.

11:40 Panel Session: Securing Funding In A Dry Market - The IndustryHas Changed, Have You?

Mark BenedykHeadThe Pfizer Incubator LLC

Matthew Q. ReberVice PresidentCowen Healthcare Royalty Partners

Matthew W. Kalnik, PhDSenior Vice President, Strategic Planning and Business OperationsNabi Biopharmaceuticals

Henry Skinner, PhDManaging DirectorNovartis Venture Funds

With limited opportunities in IPO and traditional forms of funding dried up, themarket has had to employ creative methods of financing. This session will lookat the new financing models currently being used in the pharmaceuticalindustry: Corporate alliances, grants and government contracts; Monetizingassets in your portfolio to raise capital; Assessing international licensing options;Utilizing partnering as a means to gain capital.

12:25 Networking Lunch For All Conference Attendees

Sponsored by:

1:35 Case Study Part 2: Merck/Schering Plough Merger James SchaefferExecutive Director, Worldwide Licensing and External ResearchMerck

Following up on the case study delivered at the BioNetwork East conference inMarch 2010, Dr. Jim Schaeffer joins us at BioNetwork West to continue thestory of the merger of two giants in the industry – Merck and Schering Plough.Jim will share the process used during the integration and will share significant

Conference Day 1 Monday, October 25, 2010

Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: [email protected] Web: www.bionetworkus.com 2

progress of the New Merck, the resulting pipeline, current partnership interests,and finally, the next steps for the New Merck and your partner of choice.

2:15 IP/Regulatory Update – The Pathway For BioSimilarsLen SmithPrincipal Intellectual Property CounselMedicis Pharmaceutical Corporation

It is no surprise that the healthcare reform bill was passed this spring. What isuncertain, however, is how pieces of this legislation will end up affecting thePharma space. This session will look at how the new pathway works from the“biosimilars” vs. innovators perspective and how the availability of the pathwaymight relate to deal making in the future.

2:50 Refreshment Break And Networking Opportunity

3:30 The Perfect Pitch: Biotech Investment ChallengePresented by:

Thomas AbbottPresidenti3 Pharma Informatics

In this groundbreaking session, 4 Biotechs will be given the opportunity topresent their “perfect pitch” to our audience of potential partners andinvestors as well as to our panel of experts.

Here’s how it works:Each Biotech will give a 20-minute company presentation. Then our panelists,VCs and Investment Banks will give their feedback on the strengths of thepitches just heard, highlighting the portions of the presentations that piquedtheir interest. This will give the presenting companies, as well as the audience,insight into what sparks the interest of potential partners and investors. Thissession is a must attend for Pharma, Biotechs, and the investment community.

The panelists will then have a chance to confer and choose “the perfect pitch”which will be presented at the awards ceremony cocktail reception immediatelyfollowing the afternoon’s presentations.

Panel of ExpertsDavid DonabedianVice President, Strategic Alliances, US CEEDDGlaxoSmithKline

Fred AslanVice PresidentVenrock

Kim KamdarPrincipalDomain Associates LLC

3:30-3:50 Biotech #1 Presentation 3:50-4:10 Biotech #2 Presentation 4:10-4:30 Biotech #3 Presentation 4:30-4:50 Biotech #4 Presentation 4:50-5:30 Feedback From Our Panel Of Experts

*For more information on how you can participate in the Biotech InvestmentChallenge, please contact Mimi Fox at 416-597-4808 or [email protected]

5:30 Awards Ceremony And Cocktail Reception For All AttendeesPresented by:

The “Perfect Pitch” Awards Ceremony and Cocktail Reception will be held directlyfollowing this afternoon’s Biotech Investment Challenge. The award, presentedby i3 Pharma Informatics and our panel of expert judges, will be given to the bestcompany pitch heard in the afternoon’s session. Join all conference attendees tohear who our panel of experts have chosen as the “Perfect Pitch” for 2010.

3Sponsors:

Conference Day 2 Tuesday, October 26, 2010

7:45 Networking Breakfast For All Attendees Conference Registration Sponsored By:

8:30 Chairperson’s Opening RemarksJeff TottenVice PresidentDean & Company

8:45 The Morning After - Ensuring Partnerships Work In The HarshReality Of Daylight

Robert WillsVice President Alliance Management, Pharmaceuticals GroupJohnson & Johnson

David DonabedianVice President, Strategic Alliances, US CEEDDGlaxoSmithKline

Laura PierceVice President, Alliance ManagementBayer HealthCare Pharmaceuticals

Alison ShurellVice President, Product MarketingIntralinks

Troy WindtSenior Director, Corporate DevelopmentUpsher-Smith

Maintaining relationships to work efficiently and effectively over time isparamount in a successful partnership. This session will examine the role ofthe alliance management function in today’s partnering landscape.• Pinpointing specific examples of the benefits realized through effectively

managing your relationships• Measuring the success of an alliance- outlining the metrics to gauge

effectiveness• Providing the new team with a secure and neutral platform for information

sharing and collaboration to ensure open communication throughout thelife of the partnership

9:45 Case Study: Sanofi-Aventis And Intelliject - North AmericanLicense For A Novel Epinephrine Auto-InjectorThomas Wiatrowski Director, U.S. Business DevelopmentSanofi-Aventis

Kris FordVice President Business DevelopmentIntelliject

This case study will explore the recent deal between sanofi-aventis and Intellijectfrom each side's perspective. This session will discuss the motivations behind thepartnership and include the following: 1) Brief company overview, 2) Productoverview, 3) Deal scope & terms, 4) Strategic considerations that led to the idea,5) For s-a, why IJ & this deal; for IJ, why s-a & this deal, 6) The process, 7) Updateon the status of the relationship today, 8) Lessons learned.

10:25 Refreshment Break And Networking Opportunity

11:10 Hearing From The Little Guy - Spotlight On Small BiotechsYear after year, we hear from Big Pharma on what they look for in potentialpartners. But partnering is a two-way street. These panel sessions will bringtogether representatives from biotech companies and Big Pharma companies tooffer their insight on the following:

Part 1- Defining The Difficulties Small Companies Face In FindingA Partner In Big PharmaJohn MendleinFormer CEOAdnexus Therapeutics

Matthew MeyerVice President Business DevelopmentCerimon

This panel session will highlight the problems small Biotechs face when trying totraverse the big Pharma partnering market. Panelists will share their insights onthe following: 1) What is the follow up process like for inquiries with big Pharmaand how can it be improved?; 2) Outlining the process for finding theappropriate person withi your therapeutic area: How easy is the process? Whatcould be changed? and 3) Highlighting other areas of this process that poseproblems for small companies

11:50 Part 2- In A Competitive Bidding Process - What Do SmallCompanies Look For In A Big Pharma Partner?

Katrine BosleyCEOAvila

Jason RhodesExecutive Vice President and Chief Business OfficerEpizyme Corporation

It’s true that in most cases big Pharma has its pick of biotech companies. Butin a competitive bidding process, this is not the case. This session will bringtogether representatives from small Biotechs that have gone through acompetitive bid to better understand the following:• Identifying the due diligence process for a small company• What attributes are important in a big Pharma partner?

12:30 Networking Lunch For All Conference Attendees Sponsored By:

1:40 Part 3 - BIG PHARMA Perspective: Defining The DifficultiesSmall Companies Face In Finding A Partner In Big Pharma

Ellen A. LubmanStrategic Transactions GroupBristol-Myers Squibb

Yael WeissDirector, Licensing & External Research - West CoastMerck Research Laboratories

Jack TupmanVice President, Corporate Business DevelopmentEli Lilly and Company

Understanding the challenges small biotechs face in gaining the partnership ofBig Pharma, it is important to also understand what Big Pharma expects andneeds from new partnerships. This panel provides important insights toprovide you with a Big Pharma perspective in building and sustainingbreakthrough partnerships.

2:20 Case Study: J&J / Takeda Co-Promotion For Velcade In JapanKyle D. KuvalankaVice PresidentMillenium: The Takeda Oncology Company

Denise McGinnVice President of Licensing & New Business Development, Pharmaceuticals Group, Johnson & Johnson

This case study will discuss the co-promotion of Velcade in Japan from theperspectives of both J&J and Takeda. From the strategic considerations that led to theidea, to the developing evaluations and steps that led to the negotiations, to the duediligence experience, the deal signing and closing, and the status of the relationshiptoday. What was in it for Takeda? For J&J? What “lessons learned” were captured?

3:00 Refreshment Break And Networking Opportunity

3:30 The Perfect Pitch: Biotech Investment ChallengeIn this groundbreaking session, 4 Biotechs will be given the opportunity to presenttheir “perfect pitch” to our audience of potential partners and investors as well as toour panel of experts.

Panel of ExpertsGregg TalbertManaging Director, Mergers and Acquisitions, Corporate Finance and Investment Banking (CFIB) Group, Eli Lilly

Frank StokesManaging DirectorR.W. Baird

3:30- 3:50 Biotech #1 Presentation 3:50- 4:10 Biotech #2 Presentation 4:10- 4:30 Biotech #3 Presentation 4:30- 4:50 Biotech #4 Presentation 4:50- 5:30 Feedback from our panel of experts

*For more information on how you can participate in the Biotech InvestmentChallenge, please contact Mimi Fox at 416-597-4808 or [email protected]

5:30 Awards Ceremony And Cocktail Reception For All Attendees

7:45 Networking Breakfast For All Attendees Conference Registration Sponsored By:

8:30 Chairperson’s Opening Remarks

9:00 Case Study: Compare And Contrast Two Co-Promotion Deals:Late Stage “Ready To Launch” vs. Early Stage Jack TupmanVice President, Corporate Business DevelopmentEli Lilly and Company

Roger GrabenSenior Vice President, Operations & Business DevelopmentKowa Pharmaceuticals America

Blake SalisburyDirector Corporate Business DevelopmentEli Lilly and Company

Michael A. JohnsonDirector Corporate Business DevelopmentEli Lilly and Company

In December of 2009, Lilly concluded two co-promotion agreements – one withKowa Pharmaceuticals of America, for a new statin that had already beenapproved in the US but not yet launched, and another agreement with IncyteCorporation, for an early stage new mechanism oral Rheumatoid Arthritiscompound. This case study will include comments/discussion from the seniornegotiators from the companies as they compare and contrast the differences inthe two deal transaction processes highlighting some of the challenges/opportunities and solutions associated with the different negotiations.

10:00 Panel Session: Understanding The VC Due Diligence Process WhenDeciding On Investing In A Company

Howard D. PalefskyManaging DirectorMontreux Equity Partners

Fred AslanVice PresidentVenrock

Kim KamdarPrincipalDomain Associates LLC

For small biotech companies, VC investment is critical to funding R&D projects intheir pipeline. With the market for investment as it is, the VC capital is not as freeflowing as it once was. Therefore, it is now more critical than ever to have a firmunderstanding of the due diligence process a VC conducts when evaluating acompany.

10:45 Refreshment Break And Networking Opportunity

11:30 Case Studies: Assessing The Impact Of The Emerging Markets OnThe Global Pharmaceutical Space

Daniel Bagi M.D.Managing DirectorRiso Pharma Tech Inc.

Part 1: Case Study BRIC (11:30-12:15)Part 2: Case Study: MENA (12:15-1:00)

It comes as no surprise that the emerging markets will play an integral role in thegrowth of the pharmaceutical industry. By conservative estimates, the E7 alone willbe spending over 100B annually on pharmaceutical products by 2020. This section ofthe agenda will focus on trends in the emerging markets as well as highlightcompanies that have successfully capitalized on these growth markets.

1:00 Networking Lunch For All Attendees

2:00 End Of BioNetwork 2010

4 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: [email protected] Web: www.bionetworkus.com

Conference Day 3 Wednesday, October 27, 2010

5Sponsors:

Upsher-Smith is constantly looking for strong and trustedpartnerships through licensing, joint ventures, profit sharing, co-development and co-marketing arrangements. Upsher-Smith has a

wide U.S. distribution network, experienced sales force and established customerrelationships within all customer segments. Looking to the future, Upsher-Smith isfocused on: • Building our current product pipeline • Co-promoting and acquiring women’s health products ready for commercialization • Developing, in-licensing and acquiring CNS products focused primarily on treatments

for epilepsy & Parkinson’s disease.Our vision is to become a leader in providing therapies that empower people sufferingfrom central nervous system (CNS) diseases to lead healthy, productive lives. Our focusis simple: Advancing pharmacotherapy. Improving life™.

Dean & Company is a strategy consulting firm with aunique mix of both traditional business strategy work anda range of investing activities for large corporations,

technology start-ups, and equity funds. We work with senior executives to dramaticallyimprove and sustain their company's performance. Dean & Company has anestablished, highly successful track record in generating actionable and quantifiableresults for our clients in the Life Sciences. These include a number of the largest globalcompanies as well as emerging leaders in the Pharmaceuticals, Biotechnology, andMedical Devices & Technology industries. We additionally have developed specializedexpertise in the Vaccines industry. The hallmark of our work in life sciences, as in otherindustries, is our ability to deliver highly quantitative, analytic-driven solutions tocomplex business problems and the development of practical, action-orientedrecommendations and their associated measurable impact on the bottom-line. Our lifesciences capabilities extend across the following industry challenges and issues:Licensing/Strategic Alliances/M&A Due Diligence, Portfolio/Life Cycle Management,Product Commercialization & Launch, Manufacturing & Distribution Strategy,Competitive Intelligence/Benchmarking, Marketing Strategy, Pricing & Reimbursement,R&D Productivity. www.dean.com

IntraLinks® provides enterprise-class solutions which facilitatethe secure, compliant and auditable exchange of criticalinformation, collaboration and workflow management inside

and outside the enterprise. Our on-demand solutions help you organize, manage, shareand track information, enabling you to accelerate your workflow, optimize yourbusiness processes and realize new profit potential. Since 1997, IntraLinks has beenused on critical business processes by more than 750,000 users from 90,000organizations worldwide, including 10 of the top 10 pharmaceutical companies andhundreds of biotechs. IntraLinks counts 800 of the Fortune 1000 as clients, includingenterprises such as AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bankand the FDIC. For more information, visit www.intralinks.com.

Over 25 years, ZS Associates has helped clients in more than 70 countriesmeasurably improve their results through our comprehensive expertise insales and marketing consulting, capability building and outsourcing. Ourclients include multinational, midsize and entrepreneurial companies around

the world, with a deep and long-standing emphasis on the healthcare sector, and thepharma/biotech sector in particular. Through our business development and licensingpractice area, we support both large and small pharma/biotech companies with servicesranging from strategic portfolio evaluation and business development strategy toevaluation of specific potential partners and deals. ZS has more than 1,300professionals serving clients from 19 offices worldwide. www.zsassociates.com

Sanofi-Aventis, a leading global pharmaceutical company,discovers, develops, and distributes therapeutic solutions toaddress the world’s expanding healthcare needs. We work to

prevent and treat the diseases that we know of today, as well as those we may facetomorrow. With approximately 100,000 dedicated professionals in more than 100countries, sanofi-aventis is devoted to advancing healthcare around the world. We arecommitted to maintaining the innovative approach to pharmaceuticals established byour parent company, headquartered in Paris, France. Our U.S. affiliate, withheadquarters in Bridgewater, New Jersey, employs approximately 15,000 professionalslocated throughout the country. Sanofi-aventis, U.S. is a dynamic healthcareorganization working to meet the needs of physicians and their patients. At sanofi-aventis, each and every day we work for what really matters: health .For moreinformation, visit www.sanofi-aventis.us

Campbell Alliance is the leading managementconsulting firm specializing in the pharmaceutical andbiotechnology industry. The firm's clients include most

of the world's top-20 pharmaceutical companies, as well as numerous emerging andmidsize firms. Campbell Alliance is organized into practice areas, each specializing in acritical industry function: Brand Management, Business Development, ClinicalDevelopment, Managed Markets, Sales, and Trade and Distribution. From its locationsin Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston,Philadelphia, New York City, Atlanta, and London, the firm serves clients throughoutNorth America, Europe, and Japan. For more information on Campbell Alliance, pleasevisit http://www.campbellalliance.com

EvaluatePharma® is the premier source for commercialanalysis in the pharma and biotech sector, deliveringexclusive, trusted insight into industry performance. For

industry insiders and the investment sector, EvaluatePharma® supports value-enhancingbusiness decisions with unrivalled proprietary insight. EvaluatePharma® sets new industry standards by providing consensus forecasts onglobal drug sales. Our expertise and innovative approach has driven other pioneeringdevelopments including Merge Company tool, Calendar of Events and interactive NPVAnalyzer. But it's not just our expertise that sets us apart. The reliability of our data and depth ofcoverage provide clients with commercial insights simply not available anywhere else.

Gerson Lehrman Group (GLG) manages the world’s leading expertnetwork and provides software and services to support a marketplace forexpertise. GLG's unparalleled network of leading expert consultants,known as the GLG CouncilsSM, includes more than 175,000 subject

matter experts and many key opinion leaders (KOLs) who educate and provide insightto decision makers worldwide. Healthcare companies use GLG to accelerate businessdevelopment research and gather superior market intelligence. GLG’s expertise reachesevery sector of the healthcare industry, from the mid-sized and most specializedorganizations to some of the largest pharmaceutical, biotechnology, healthcare services,and medical device and supply companies in the world. Visit us at www.glgroup.com.

i3 is a full-service, global contract research company providingclinical research services for biotech and pharmaceutical clients. i3takes a 360-degree view of health care to help its global

pharmaceutical, biotechnology, and medical device clients bring safe and effectiveproducts to market quickly and help demonstrate their value, leading to increased ROIand better patient care. i3’s Pharma Informatics combines unparalleled data assets, online tools, and scientificexpertise to help you attain a clearer understanding of your products’ potential andcorresponding market dynamics—so you can make more rapid, informed decisionsthroughout development and commercialization.

Founded in 1876, Eli Lilly and Company is now the 10th largestpharmaceutical company in the world. Lilly has steadfastly remainedindependent, but not isolated. Across the globe, Lilly has developed

productive alliances and partnerships that advance our capacity to develop innovativemedicines at lower costs. Lilly is consistently ranked as one of the best companies in theworld to work for, and generations of Lilly employees have sustained a culture thatvalues excellence, integrity, and respect for people. Lilly's global employees numberapproximately 40,000, and our medicines are marketed in 143 countries. Lilly has majorresearch and development facilities in eight countries and conducts clinical trials inmore than 50 countries. Lilly makes medicines that help people live longer, healthier,more active lives.

Symphogen is developing superior antibody therapeutics to helppeople with seri¬ous diseases. With its proprietary Symplex™discovery and Sympress™ manufacturing platforms, thecompany captures the diversity and specificity of the natural

immune response in rationally designed recombinant antibody composi¬tions.Symphogen is maturing a diversified pipeline of internal and partnered prod¬uctsacross multiple indications including cancer and infectious disease. Its technologies andexpertise within the antibody field have been validated through corporate partnershipswith pharmaceutical companies in the US, Europe, and Japan. Symphogen’s corporateoffice is located in Lyngby, Denmark and employs 70 people. Symphogen’s USsubsidiary, Symphogen, Inc. is headquartered in Princeton, NJ.

About Our Sponsors

SPONSORSHIP OPPORTUNITIES AVAILABLE

Don’t miss your chance to be in front of the top pharmaceutical and biotech companies in North America. If you are offering a solution, service, or technologythat will help companies improve research and development, search and evaluation, licensing, strategic alliances, due diligence, or simply want to show howyou are the partner of choice in fueling opportunities for increasing drug pipelines, contact Jodi Richter, Director of Sponsorship and Sales, 646-200-7485 or email [email protected].

BioPharm Insight provides the most comprehensiveinformation and forward-looking insight to help you easily

find the answers you need within the Biotechnology and Pharmaceutical industry.It includes the entire drug discovery and development pipeline, approved drugs,licensing deals, pharmaceutical sales/projections, management contacts andmore.

BioPharm International integrates the science and business ofbiopharmaceutical research, development, and manufacturing.

We provide practical, peer-reviewed technical solutions to enablebiopharmaceutical professionals to perform effectively. BioPharm is the longest-running peer-reviewed publication serving an international audited audienceinvolved in the development, manufacturing of therapeutics and management ofrelated business issues.

Bioresearch Online is the premier sourcing site for industryprofessionals. Use our supplier directory, product showcase, and

offline search service to expedite your discovery of new products and services.Our goal is to help buyers, like you, identify and select the right suppliers.

BioWorld Today, the newspaper of record for the biotechnologyindustry, is read by thousands of biotechnology professionals

worldwide for its hard-hitting, objective news reporting and insightful analysiscovering news on public companies and hard-to-find information on privatecompanies. Delivered by e-mail every business morning, we are also foundexclusively online at www.BioWorld.com.

CanBiotech - A Portal and B2B Outsourcing Marketplace for theBiotech and Pharmaceutical Industry. The Marketplace features theOutsourcing Services Showcase; the Portal features our

biopharmaceutical and venture capital directories and databases. Publicationsinclude the Bio Outsourcing Asia© Publication. www.canbiotech.com

CurrentPartnering is an online provider of best practice,business information and intelligence for dealmakers.

The core of our service is to provide access to latest best practice, businessintelligence and information for dealmakers. We search out the latest informationso you don’t have to and place it in one location, saving you precious time andresources. CurrentPartnering is a publisher in its own right, publishing a series ofreports each year and providing access to critical decision making and bestpractice intelligence from leaders in the partnering field. Our most recent reporttitles include:• Option & Evaluation Agreements in Pharma & Biotech• Royalty Financing Terms and Agreements in Pharma, Biotech & Diagnostics, 2nd

Edition• Practical Guide to Finding Partners in Pharma & Biotech, 3rd Edition• Clinical Stage Partnering Terms and Agreements in Pharma & Biotech, 2nd

EditionFor more information about us, please visit www.currentpartnering.com

Cutting Edge Information delivers an innovative approach tocomprehensive pharmaceutical and biotechnology benchmarkingdata. CEI offers objective, proprietary primary and secondary research

on critical industry issues. CEI offers customized consulting services and a growinglibrary of targeted and insightful pharmaceutical research reports.

Drug Discovery Online covers drug discovery like no otherInternet site. Each day we present the most interesting, useful

feature stories, case studies, industry news, and newswire feeds related to thescience and business of discovering new drugs. Throughout the year DrugDiscovery Online presents news and opinions on the latest discovery technology,from organic synthesis and the manual isolation of new compounds from exoticplants, to combinatorial chemistry and high-throughput screening.

FierceBiotech is the biotech industry's daily monitor. Seniorbiotech industry professionals rely on FierceBiotech to stay up to

speed on biotech corporations, FDA approvals & regulations, industry mergers &acquisitions, clinical trials, and more through our comprehensive website and freeemail newsletter. http://www.FierceBiotech.com

Georgia Bio (www.gabio.org) is the private, non-profit associationrepresenting more than 300 pharmaceutical, biotechnology,

medical device and diagnostic companies, healthcare systems, universities,research institutes and other organizations involved in the research anddevelopment of life sciences products that improve the health and well-being ofpeople, animals and the environment worldwide.

Laboratory Network is the premier Internet source of usefuland timely information about the laboratory industry. The site

is directed to chemists, researchers, laboratory managers and research directors,as well as users, purchasers and manufacturers of laboratory equipment,chemicals, and supplies. Laboratory Network provides daily news updates andreports on business and technology trends vital to the industry.

Established in 1965, the Licensing Executives Society (U.S.A. andCanada), Inc. (LES) is a professional society comprised of over 6,000members engaged in the transfer, use, development, manufacture

and marketing of intellectual property. The LES membership includes a widerange of professionals, including business executives, lawyers, licensingconsultants, engineers, academicians, scientists and government officials. Manylarge corporations, professional firms, and universities comprise the Society'smembership. Licensing Executives Society (U.S.A. and Canada), Inc. is a membersociety of the Licensing Executives Society International, Inc. (LESI), with aworldwide membership of over 12,000 members in 30 national societies,representing over 80 countries.

Life Science Leader strives to be an essential business tool forLife Science executives. The editorial is designed to providereaders with content pertaining to the life cycle of Life Science

products and services. Our goal is to provide information that helps high-levelindustry personnel improve profits and overcome hurdles within the industry.

For more than 25 years, Med Ad News has provided thebusy pharmaceutical executive with need-to-know business

information. Each issue delivers broad coverage and penetrating analysis ofissues, events, trends, and strategies shaping the pharmaceutical industry.Published monthly, Med Ad News provides exclusive content examining historicaltrends pertaining to and current events affecting the sales and marketing ofmedicines and the companies that manufacture them. To learn more about MedAd News and other products from Canon IMM Inc. visit www.pharmalive.com orcall 215-944-9800.

Published by Espicom Business Intelligence, Pharma AgreementNews is the twice-monthly business publication that concisely

reports on hundreds of agreements and deals between phamaceutical companiesworldwide. For further information and to order your subscription today, visitwww.espicom.com/pan

Pharmaceutical Online is the online industry standard forpharmaceutical manufacturing. Use our supplier directory,

product showcase, and offline search service to expedite your discovery of newproducts and services. Our goal is to help buyers, like you, identify and selectsuppliers.

Pharma Connections Worldwide® is the leading professionalbusiness networking website focused in the Pharmaceutical,Biotechnology and Life Sciences research industry. Our goal is

to provide a conduit for delivery of premiere content coupled with the rightclientele in order to facilitate business development opportunities amongindustryprofessionals responsible for making key decisions in a global marketplace.

PharmaVOICE magazine, and its supporting VIEW publications,provide commentary about the challenges and trends impacting

the life-sciences industry, covering a range of issues from molecule throughmarket. PharmaVOICE's more than 17,500 U.S.-based subscribers are also keptabreast of the latest trends through additional media resources, includingWebSeminars, Podcasts, Videocasts, and White Papers.

The Scientist, the award-winning magazine of the life sciences,provides compelling print and online coverage of the latestdevelopments in the life sciences including research,

technology, and business. We entertain and inform our readers, keeping themup-to-date with latest news, events, culture, innovations and career advice. Visitus at www.the-scientist.com.

Updated daily on the web or twice-monthly in print, WorldGeneric Markets distils the important generic market newsworldwide. Published by Espicom Business Intelligence, World

Generic Markets is fast becoming the publication of choice for drug developers,the pharmaceutical manufacturers, service companies, commerce, investors andregulators - make sure you get the benefits too! For further information and toorder your subscription today, visit www.espicom.com/wgm

About Our Media Partners

6 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: [email protected] Web: www.bionetworkus.com

7Sponsors:

Ritz Carlton Laguna NiguelOne Ritz Carlton Drive, Dana Point, CA 92629Tel. 949-240-2000Fax. 949-240-0829 http://www.ritzcarlton.com/en/Properties/LagunaNiguel/Default.htm

Experience genuine renewal at The Ritz-Carlton, Laguna Niguel. Situatedatop a 150-foot bluff, this peaceful sanctuary soars above the standardLaguna hotels with refined elegance, a graceful atmosphere and impeccableservice. Located halfway between Los Angeles and San Diego, the luxuryoceanfront resort offers panoramic white-water views of the Pacific. TheRitz-Carlton, Laguna Niguel is a luxury resort like no other.

BioNetwork has procured a special conference rate of $330.00 pernight (plus tax). To book your reservations, call the Ritz Carlton LagunaNiguel at 949-240-2000 or 1-800-241-3333 and identify yourself as aBioNetwork attendee. Rooms are limited and are on a first come, firstserved basis, so make your reservations as soon as possible. The discountedrate expires September 24th, 2010. After September 24th, rooms may stillbe available, so inquire with the hotel if you have missed the cut off date.

Please Note:• To secure your team discount, register online at www.bionetworkus.com or contact Bill Penney at

1-866-691-7771 or [email protected] • Team discounts must be booked and paid for at the same time. Team discounts do not apply to

sponsoring or exhibiting companies or non pharmaceutical, biotech company.• All discounts are taken off the full conference price. No two discounts or offers can be combined.• Payment is due in full at the time of registration. Your registration will not be confirmed until

payment is received and may be subject to cancellation• For payment methods and to register now, please visit www.bionetworkus.com.

Delegate Substitutions And Cancellations: • You may substitute delegates at any time by providing reasonable advance

notice to WBR. • For any cancellations received in writing not less than thirty (30) days prior to

the conference, you will receive a 75% credit to be used at another WBRconference which must occur within one year from the date of issuance ofsuch credit. An administration fee of 25% of the contract fee will be retainedby WBR for all permitted cancellations.

• There are no refunds given under any circumstances.

PURCHASE SELECT AUDIO PRESENTATIONS* FROM THIS EVENT!

Can't make it to BioNetwork 2010 or worried that there is too much information to digest in afew short days at the event? No need to worry. You can purchase select audio presentations toshare with your entire team.

Register for the event today and for an additional $250 gain access to select audiopresentations from this event. Can’t attend? Purchase the CD-ROM only for $580

*Presentations available are at the approval of conference speakers. Allow 3-4 weeks after eventdate for shipping.

Hotel Information

Find out how you can sponsor BioNetwork 2010. Unlike huge industryevents, BioNetwork allows you to meet senior executives from differentPharmaceutical and Biotech companies on a one-to-one basis. Forsponsorship inquiries please contact: Jodi Richter, Director ofSponsorship and Sales, 646-200-7485 or [email protected].

Sponsorship Opportunities Available

• John Wayne/Orange County Airport; SNA (25 minutes/23 miles)http://www.ocair.com/

• Long Beach Airport; LGB (45 minutes/44 miles) http://www.lgb.org/

• Los Angeles International Airport; LAX (60 minutes/63 miles) http://www.lawa.org/

• San Diego Lindbergh Field Airport; SAN (75 minutes/67 miles) http://www.portofsandiego.org/

Airport Options

If you're already registered or are planning to register for BioNetwork2010, tell us about five people you would like to meet at the event. Wewill reach out to them on your behalf to get them registered. Once theyregister, we will notify you, so you can set up one-on-one meetings withthem onsite at BioNetwork.

Send your list of names, including job title, company, phone and emailaddress to [email protected] or go to our website atwww.bionetworkus.com and complete the online form.

Tell Us Who You Want To Meet AtBioNetwork 2010!

In these innovative sessions eight Biotechs will be given the opportunity topresent their “perfect pitch” to our audience of potential partners andinvestors as well as to our panel of experts.

Each Biotech will give a 20 minute company presentation highlighting theircurrent projects. Then our panelists, consisting of big Pharma, VCs andInvestment Banks will give their feedback on the strengths of the pitches justheard- highlighting the portions of the presentations that piqued their interest.This will not only give the presenting companies the platform to attract newpartners, but will also give the presenting companies, and audience alike,insight into what sparks the interest of potential partners and investors. Thissession is a must attend for Pharma, Biotechs, and the investment community.

The panelists will then have a chance to confer and choose “the perfect pitch”which will be presented at the awards ceremony cocktail receptionimmediately following the afternoon’s presentations.

If your company is interested in joining one of the InvestmentChallenge afternoons, contact Mimi Fox at 416-597-4808 or [email protected]! Spaces are limited so sign up today!

The Perfect Pitch: Biotech Investment Challenge

Please inquire about discounted rates at [email protected] or contactMimi Fox at [email protected], 416-597-4808 to learn more.

Small Biotechs & University Pricing Available!

Conference Pricing

Register & Pay Register & Pay Register & Pay By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To

Get $600 Off Get $400 Off Get $200 Off Full Price

3 Day Conference $2,600 $2,800 $3,000 $3,200

Pricing

Register & Pay Register & Pay Register & PayBy 7/30/2010 To By 8/31/2010 To By 9/30/2010 To

Get $800 Off Get $600 Off Get $400 Off Get $200 Off

3 Day Conference $2,400 $2,600 $2,800 $3,000

Group Discountsfor Teams of 2or More

For every registration received for Bio Network,WBR will donate a portion of the registration fee toSmile Train. For more information about WBR’sinvolvement with Smile Train, please [email protected].

Registration Information

WBR535 Fifth Avenue, 8th FloorNew York, NY 10017

When registering please provide the code above.

Your priority booking code is:

10386.005/GS

Attention Mailroom: If undeliverable to addressee, this time sensitive information should be forwarded to the VP of Business Development

October 25-27, 2010The Ritz-Carlton,Laguna Niguel, CAwww.bionetworkus.com

Sponsors:O

rganized by:

Call: 1-888-482-6012 or 1-646-200-7530

Fax: 1-646-200-7535Em

ail: bionetwork@

wbresearch.com

W

eb: ww

w.bionetw

orkus.com

REG

ISTERN

OW

!

Sou

rce Fun

din

g. Fo

rge Partn

ership

s. Man

age R

elation

ship

s.O

ctob

er 25-27, 2010• Th

e Ritz-C

arlton

, Lagu

na N

igu

el, CA

• ww

w.b

ion

etwo

rkus.co

m

Special

Disco

un

tsA

vailable!

See pg. 7 for details

Do

n’t M

iss These Exclu

sive Netw

orkin

g O

pp

ortu

nities

Un

iqu

e To B

ioN

etwo

rk:

•30+

private one-to-one meeting

opportunities

•23 interactive and educational panelsessions and case studies presentedby executive level industry leaders

•Biotech Research Presentations atthe Perfect Pitch: BiotechInvestm

ent Challenge

•5 netw

orking refreshment breaks

•3 netw

orking breakfasts

•3 netw

orking lunches

•2 rew

arding cocktail receptions

•1 essential opportunity to sourcefunding, forge partnerships, andm

anage relationships with the

decision makers in your industry

“BioNetwork is a top tier biotech/pharma industryconference, integrating business development

executives with many strong partnering functions - great venues & very productive results”

- Jim Hattersly, Vice President, Corporate BusinessDevelopment, Sun Pharmaceutical Industries, Inc.

“I have always found the BioN

etwork m

eetings very productive. Due to its m

oreintim

ate setting, it is very easy to meet w

ith companies and share ideas. This setting

coupled with a w

ell organized and professionally managed conference alw

aysdelivers a positive experience.” - M

ark Den

nish

, Vice Presid

ent, B

usin

ess Develo

pm

ent, D

aiichi San

kyo

Can’t make it to:

or afraid there is toomuch information to digest in just afew days?

Get Access to hours of valuablesessions and take-ways anytime,anywhere... Now you can view this outstanding conferencecontent on your PC or laptop with a CD-ROM thatputs you front and center at these informativesessions. You'll hear our expert speakers as theytake you through the PowerPoint slides thatillustrated their talks.

This Session Content is available for afraction of the registration price. You can view and listen to the content whenyou want, where you want and as many timesas you want.

And if you attend BioNetwork 2010, thisConference CD-ROM set is only $250! (That’s a $580 value!)

VIP Package: $250(Select any package to attend the event

and for an additional $250 get theconference CD ROM*)

CD ROM ONLY: $580 *

*Presentations available are at the approval of conferencespeakers. Not all presentations will be published. Allow 3-4 weeksafter event date for shipping.

This user friendly format allows you to:• Gain valuable insight from your peers and

competitors in various Fortune 500 Industrieswithout leaving the office.

• Share with your colleagues at work. • Stay up to date with the latest strategies, tactics

and trends in your industry.

Now you can share what you learnt at BioNetwork 2010, with your colleagues. Don’t leave them in the dark. Purchase the CD ROM today!

Organized by: